About Liz Seegert
Liz Seegert is an independent health journalist based in New York’s Hudson Valley, who writes about caregiving, dementia, access to care, nursing homes and policy in her role as AHCJ’s Health Beat Leader for Aging. Seegert helps provide context for reporting on this multidimensional issue with story posts, tip sheets, analysis, data and one-on-one interviews with aging experts.

Photo by Tim Doerfler via Unsplash
The FDA granted full clinical approval to Leqembi (lecanemab) on Thursday, July 6, making it only the second new drug approved to fight Alzheimer’s disease and the first to receive full authorization from the agency.
The approval follows unanimous endorsement of the drug’s safety, efficacy and clinical benefit by an independent advisory committee in June. The anti-amyloid drug had already received accelerated approval in January 2023. Full FDA authorization is a big step for potentially thousands of people with mild to moderate Alzheimer’s, who may be eligible for treatment.
Continue reading →
Liz Seegert is an independent health journalist based in New York’s Hudson Valley, who writes about caregiving, dementia, access to care, nursing homes and policy in her role as AHCJ’s Health Beat Leader for Aging. Seegert helps provide context for reporting on this multidimensional issue with story posts, tip sheets, analysis, data and one-on-one interviews with aging experts.